<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03482180</url>
  </required_header>
  <id_info>
    <org_study_id>12-OA-8301</org_study_id>
    <nct_id>NCT03482180</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Parallel Phase III Study to Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kuhnil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kuhnil Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine variation rate of Non-HDL with KI1106 comparison Atorvastatin monotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomly assigned to two groups (KI1106 or Atorvastatin monotherapy) after 4 weeks run-in
      period and prescribed KI1106 or Atorvastatin for 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 4, 2016</start_date>
  <completion_date type="Actual">March 23, 2018</completion_date>
  <primary_completion_date type="Actual">May 16, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation rate of Non HDL-C</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variation rate of TG</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation rate of Non HDL-C</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation rate of TC</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation rate of LDL-C</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation rate of VLDL-C</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation rate of Apo A-I</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation rate of Apo B</measure>
    <time_frame>4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Investigational Group- KI1106</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KI1106 tablet - daily administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group - Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin Calcium 20mg - daily administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KI1106 4g, QD</intervention_name>
    <description>KI1106 4 Capsules</description>
    <arm_group_label>Investigational Group- KI1106</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin Calcium 20mg, QD</intervention_name>
    <description>Atorvastatin Calcium 20mg</description>
    <arm_group_label>Control Group - Atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Screening Visit

               -  Age: 20-80

               -  High risk for cardiovascular disease according to NCEP APT III

               -  TG≥300mg/dL and 160mg/dL&gt;LDL-C≥100mg/dL for subjects who were not taking statins
                  for 4 weeks

               -  500mg/dL&gt;TG≥200mg/dL and LDL-C&lt;110mg/dL for subjects who were taking statins for
                  4 weeks

          -  Baseline Visit

               -  500mg/dL&gt;TG≥200mg/dL

               -  LDL-C&lt;110mg/dL

               -  Reduction of LDL-C comparing screening visit

        Exclusion criteria:

          -  The patient has histories of acute artery disease within 3 months

          -  The patient has histories of operation revasculariation or aneurysm within 6 months

          -  The patient has histories of unexplained myalgia or diagnosed myalgia or
             rhabdomyolysis

          -  The patient has histories of effect able disease to the procedure and clinical trial
             result
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>kyungshun Shin, Dr</last_name>
    <role>Study Director</role>
    <affiliation>manager</affiliation>
  </overall_official>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>March 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>November 15, 2018</last_update_submitted>
  <last_update_submitted_qc>November 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

